<DOC>
	<DOCNO>NCT02709889</DOCNO>
	<brief_summary>To assess safety tolerability rovalpituzumab tesirine subject specific delta-like protein 3-expressing advanced solid tumor .</brief_summary>
	<brief_title>Rovalpituzumab Tesirine Delta-Like Protein 3-Expressing Advanced Solid Tumors</brief_title>
	<detailed_description>This multicenter , open-label study involve multiple specific advance solid tumor type , consist dose escalation Part A follow expansion Part B . Cancer subtypes study separate disease-specific cohort Parts . Eight separate cohort enroll malignant melanoma , medullary thyroid cancer ( MTC ) , glioblastoma , large cell neuroendocrine carcinoma ( LCNEC ) , neuroendocrine prostate cancer ( NEPC ) , high-grade gastroenteropancreatic ( GEP ) , neuroendocrine carcinoma ( NEC ) , NEC , solid tumor .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>Histologically confirm , unresectable advance solid malignancy document disease progression least 1 prior systemic therapy Measurable disease define RECIST 1.1 DLL3expressing malignancy base central immunohistochemical ( IHC ) test representative baseline tumor tissue ( archived tissue onstudy biopsy ) . Positive define stain ≥ 1 % tumor cell . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Minimum life expectancy least 12 week Subjects history central nervous system ( CNS ) metastases must documentation stable improve brain image least 2 week completion definitive treatment within 2 week prior first dose Study Drug , stable dose corticosteroid . Definitive treatment may include surgical resection , whole brain irradiation , and/or stereotactic radiation therapy . ( Applicable tumor type nonCNS primary origin ) Recovery Grade 1 clinically significant toxicity ( exclude alopecia ) prior initiation study drug administration Adequate hematologic organ function confirm laboratory value Last dose prior therapy administer following time interval first dose study drug : 1 . Chemotherapy , small molecule inhibitor , radiation , and/or investigational anticancer agent ( exclude investigational monoclonal antibody ) : 2 week . 2 . Immunecheckpoint inhibitor ( e.g. , antiPD1 , antiPDL1 , antiCTLA4 ) , monoclonal antibody , antibodydrug conjugate , radioimmunoconjugates , Tcell cellbased therapy : 4 week ( 2 week document disease progression ) . Females childbearing potential must negative beta human chorionic gonadotropin ( βhCG ) pregnancy test result within 7 day prior first dose study drug . Females nonchildbearing potential postmenopausal great 1 year bilateral tubal ligation hysterectomy . Any significant medical condition , include suggest screen laboratory finding , opinion investigator sponsor , may place subject undue risk study , include necessarily limit uncontrolled hypertension and/or diabetes , clinically significant pulmonary disease ( e.g. , chronic obstructive pulmonary disease require hospitalization within 3 month ) neurological disorder ( e.g. , seizure disorder active within 3 month ) . Documented history cerebral vascular event ( stroke transient ischemic attack ) , unstable angina , myocardial infarction , cardiac symptom consistent New York Heart Association ( NYHA ) Class IIIIV ( see Appendix 12.4 ) within 6 month prior first dose study drug . Recent ongoing serious infection , include : 1 . Any active grade 3 high ( per NCI CTCAE version 4.03 ) viral , bacterial , fungal infection within 2 week first dose study drug . Routine antimicrobial prophylaxis permit . 2 . Known seropositivity active infection human immunodeficiency virus ( HIV ) . 3 . Active Hepatitis B ( surface antigen expression polymerase chain reaction ) C ( polymerase chain reaction ) infection hepatitisrelated antiviral therapy within 6 month first dose study drug . Women pregnant breastfeed Systemic therapy corticosteroid &gt; 20 mg/day prednisone equivalent within 1 week prior first dose study drug History another invasive malignancy remission least 3 year . Exceptions 3year limit include nonmelanoma skin cancer , curatively treat localized prostate cancer , ductal carcinoma situ , cervical cancer situ biopsy squamous intraepithelial lesion PAP smear . Prior exposure pyrrolobenzodiazepine ( PBD ) base drug , prior participation rovalpituzumab tesirine clinical trial , know hypersensitivity rovalpituzumab tesirine excipient contain drug formulation , unless undergoing retreatment rovalpituzumab tesirine context protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>